Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

3017 Background: Mutations of Ras/Raf lead to a sustained and constitutive activation of ERK pathway. MEK1/2 is the only enzyme that activates ERK1/2; consequently MEK1/2 is a potential target to inhibit in cancers with an activated ERK pathway. RO4987655, a potent, highly selective ATP non-competitive MEK1i with an excellent selectivity profile, was tested in a 3+3 Ph1 study design. Objectives were determination of maximum tolerated dose (MTD), recommended Ph2 dose (RP2D), dose limiting toxicities (DLTs), safety/tolerability, PK/ PD and clinical activity. METHODS: Patients (pts) with advanced/metastatic solid tumors received oral RO4987655 administered on a continuous daily dosing (QD) from 1-2.5 mg then twice daily (BID) from 3-21 mg total daily dose in 28 days (D) cycles. Blood PK samples were collected on cycle 1 (C1) [D 1, 8, 15 and 22]. Molecular target suppression was measured by pERKi in PBMC on C1 (D1, D15). Paired skin and tumor biopsies (optional) (baseline, C1D15) and sequential FDG-PET scans (baseline, C1D15, C3D1) were taken. Efficacy was measured as per RECIST. RESULTS: 49 pts in 12 cohorts were enrolled at 4 sites. Mean age 52 y, ECOG 0-1, previous chemotherapy lines median 3 (0-10). Common tumor types included melanoma (27), CRC (11) and NSCLC (3). Four reversible DLTs were observed: CPK elevation (17 mg (n=1), 21 mg (n=2) and blurred vision (21 mg). MTD and RP2D were defined as 17 mg. Most commonly related adverse events included skin (91%), GI (57%), eye (26%) and CPK disorders (44%). PK profiles showed dose-linearity, a half-life of 4 to 6 hrs and drug accumulation ~ 2 fold at steady-state. High (mean 75%) and sustained (90% of time >IC50) pERKi was observed in PBMC at RP2D. FDG PET showed large decrease in SUV at RP2D (-47%, -90% to +29%) (mean, range) which correlated with PBMC pERKi in melanoma pts. PRs and SDs (>=4 mo) were observed in 2 and 5 melanoma, respectively. CONCLUSIONS: RO4987655 showed acceptable and manageable safety profile. PK was linear for the tested dose range with moderate inter-pt variability. PD activity in PBMC associated with large metabolic FDG-PET response and preliminary encouraging antitumor activity were demonstrated at the RP2D.

Type

Journal article

Journal

J Clin Oncol

Publication Date

20/05/2011

Volume

29